Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bisphosphonates.

Michael R McClung1

  • 1Department of Medical Education, Providence Portland Medical Center and the Oregon Osteoporosis Center, 5050 NE Hoyt Street, Suite 651, Portland, Oregon 97213, USA. mmcclung@orost.com

Endocrinology and Metabolism Clinics of North America
|April 18, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment duration for romosozumab.

The lancet. Diabetes & endocrinology·2026
Same author

Low body mass index: an early warning sign for osteoporosis.

Menopause (New York, N.Y.)·2026
Same author

Tailoring menopause education to the needs of primary care clinicians: the Oregon menopause ECHO experience.

Menopause (New York, N.Y.)·2026
Same author

Considerations regarding the use of romosozumab in a patient at high risk for cardiovascular disease.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2025
Same author

Proceedings of the 2025 Santa Fe Bone Symposium: Current concepts in the care of patients with osteoporosis, parathyroid disorders, and rare bone diseases.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry·2025
Same author

Improved prediction of hip fracture using multi-faceted biomechanical computed tomography.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2025
Same journal

Navigating Adrenal Disease: A Comprehensive, Practical Guide for the Clinician.

Endocrinology and metabolism clinics of North America·2026
Same journal

Adrenal Disorders in Pregnancy.

Endocrinology and metabolism clinics of North America·2026
Same journal

Diagnosis and Management of Adrenocortical Carcinoma.

Endocrinology and metabolism clinics of North America·2026
Same journal

Pheochromocytomas and Paragangliomas.

Endocrinology and metabolism clinics of North America·2026
Same journal

Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

Endocrinology and metabolism clinics of North America·2026
Same journal

Primary Bilateral Macronodular Adrenal Hyperplasia.

Endocrinology and metabolism clinics of North America·2026
See all related articles

Bisphosphonates are effective anti-remodeling drugs for osteoporosis, offering bone-specific efficacy and fracture protection. Future bisphosphonates may improve tolerability and administration, expanding patient options.

Area of Science:

  • Pharmacology
  • Bone Biology
  • Geriatrics

Background:

  • Bisphosphonates are a cornerstone therapy for osteoporosis.
  • They exhibit bone-specific efficacy, rapid response, and protect against spine and hip fractures.
  • Their role remains significant despite the emergence of anabolic agents.

Purpose of the Study:

  • To review the established role and future potential of bisphosphonates in osteoporosis management.
  • To discuss the clinical profile and comparative effectiveness of various bisphosphonates.
  • To highlight challenges in patient selection and adherence.

Main Methods:

  • Literature review of clinical data on bisphosphonate efficacy and tolerability.
  • Analysis of in vitro potency versus clinical response data.

Related Experiment Videos

  • Discussion of emerging bisphosphonate formulations and administration routes.

    • Main Results:

    • Clinical responses to different bisphosphonates are similar, despite in vitro potency variations.
    • Existing data do not allow for direct comparison of clinical effectiveness between various bisphosphonates.
    • Newer bisphosphonates are anticipated to offer improved tolerability and administration options.

    Conclusions:

    • Bisphosphonates remain crucial for osteoporosis treatment, offering significant benefits.
    • Clinicians must optimize patient selection and adherence strategies for bisphosphonate therapy.
    • Future bisphosphonate development focuses on enhancing patient acceptance and usability.